These observations raise the possibility that selective targeting of IL-9 may yield different results as compared to Th9 cell targeting, as the anti-tumor effect of the Th9 cytokine IL-21 is not targeted by anti-IL-9 antibodies. Here, IL21 is linked to neoplasm.